Aurobindo Pharma Q3: Profit Surges 23%, Revenue Dips Amidst Green Energy Push

OTHER
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Aurobindo Pharma Q3: Profit Surges 23%, Revenue Dips Amidst Green Energy Push
Overview

Aurobindo Pharma delivered a mixed Q3 FY26, with standalone Profit After Tax (PAT) surging 23.3% YoY to ₹5,820.7 million, despite a 5.4% revenue dip. Consolidated PAT grew 7.6% to ₹9,098.0 million on 8.9% revenue growth. The company also approved a ₹66 crore investment for a 26% stake in renewable energy firm Garuda Renewables and a subsidiary merger to optimize operations. An exceptional item related to new Labour Codes impacted results.

📉 The Financial Deep Dive

The Numbers: Aurobindo Pharma announced its Q3 FY26 results, showcasing robust profit growth but a decline in standalone revenue. On a standalone basis, Profit After Tax (PAT) for the quarter ended December 31, 2025, rose 23.3% year-on-year to ₹5,820.7 million. However, revenue from operations saw a 5.4% decrease YoY, settling at ₹27,263.8 million. Basic Earnings Per Share (EPS) improved to ₹10.02 from ₹8.13 in the prior year quarter.

Consolidated figures presented a healthier picture in terms of revenue, which increased by 8.9% YoY to ₹86,045.1 million. Consolidated PAT saw a 7.6% uptick to ₹9,098.0 million. For the nine months ended December 31, 2025, consolidated revenue grew 7.1% YoY to ₹2,46,332.4 million, while PAT remained nearly flat, showing a marginal increase of 0.05% to ₹25,821.3 million.

An exceptional item of ₹173.8 million standalone and ₹653.3 million consolidated was recognized, stemming from increased gratuity and leave liabilities due to new Labour Codes.

The Quality: The sharp increase in standalone PAT, despite lower revenue, suggests improved cost management or a favourable product mix in the quarter. The flat consolidated PAT for the nine-month period, however, warrants closer examination of operational efficiencies across the group. The exceptional item provides a one-off drag on reported profits.

Risks & Outlook: The primary concern remains the decline in standalone revenue, which investors will monitor closely. On the strategic front, Aurobindo Pharma's Board has approved investing ₹66 crores for up to a 26% stake in Garuda Renewables to procure hybrid wind and solar energy. This move aims to achieve significant power cost savings and enhance its ESG profile, with completion expected within six months. Additionally, a merger of Auro Vaccines Private Limited with Curateq Biologics Private Limited is proposed to streamline group entities and reduce costs. The appointment of Dr.(Mrs.) Punita Kumar Sinha as an Additional Director brings valuable expertise in capital markets and governance. The company operates in a single reportable segment: Pharmaceuticals.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.